Proton therapy CBCT imaging solution across Proteus^® Portfolio providing clarity and confidence in IGPT

 IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the leading provider of proton therapy solutions for the treatment of cancer, announces the introduction of AdaPTinsight XR, the next generation of its Cone Beam Computed Tomography (CBCT) imaging capabilities, designed to enhance visualization and support confident decision-making in image-guided proton therapy (IGPT).

Building on the existing AdaPTinsight solution, AdaPTinsight XR¹ helps clinicians reduce ambiguity in daily assessments and fully leverage the precision potential of Proteus^® systems. Reinforcing clarity, confidence, and upgradeability, the solution strengthens IBA’s commitment to continuously advancing imaging performance across both installed and future proton therapy systems, making proton therapy more accessible and helping it become the standard of care for more cancer indications.

AdaPTinsight XR is built on one clear promise: clarity and confidence. It delivers state-of-the-art isocentric IGPT with significantly improved image quality through enhanced contrast resolution, advanced artifact suppression, and next-generation image calibration and reconstruction.

AdaPTinsight XR also aligns with IBA’s long-term platform roadmap, as it represents the next evolution of the AdaPTinsight imaging solution. It further strengthens the Proteus^® family as a scalable, future-ready image-guided proton therapy platform and supports continued innovation and upgradeability throughout the system lifecycle for both existing and future installations.

“The improved contrast and sharpness could potentially enable faster patient positioning due to enhanced soft-tissue visualization,” said Prof. Dr. Frank Lohr, Director of the Proton Therapy Unit at the Proton Therapy Center of SUIT in Trento.

Olivier Legrain, Chief Executive Officer of IBA, added: “With AdaPTinsight XR, we are pleased to introduce the latest imaging capabilities for our proton therapy systems. Imaging is central to positioning accuracy, treatment margins, and the speed of daily clinical decisions, and continued progress in image quality can influence how clinical practice evolves. As this capability is introduced, we look forward to working closely with our users and learning from their feedback as they explore new ways to use imaging with greater confidence.”